#Vienna #Austria #Hoth Therapeutics #Robb Knie #BIO-Europe

Hoth Therapeutics CEO to Present at BIO-Europe 2025

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a pioneering clinical-stage biopharmaceutical company, is set to have its CEO, Robb Knie, present at the esteemed BIO-Europe 2025 Conference in Vienna, Austria, which is scheduled for November 3-5, 2025. The conference is recognized as one of the foremost global platforms for biopharmaceutical innovation and collaboration.

Highlighting Major Developments

During his presentation, Mr. Knie will spotlight Hoth's two leading development programs that are making waves in the healthcare sector:

1. HT-001: This topical therapeutic aims to alleviate rash and skin toxicity often experienced by patients undergoing cancer treatments, specifically those utilizing EGFR inhibitors and radiotherapy.
2. HT-KIT: This precision oncology program targets cancers that are attributed to dysregulated KIT signaling, reflecting Hoth's commitment to addressing specific genetic drivers of cancer.

Robb Knie expressed enthusiasm about the conference, stating, "BIO-Europe is one of the premier global events for biopharma partnering and innovation. We are excited to share the progress on our lead programs and engage with potential collaborators who share our vision of developing breakthrough therapies for patients with high unmet medical needs."

These innovative treatments are designed to greatly improve the quality of life for patients dealing with the side effects of cancer therapy, thereby exemplifying Hoth Therapeutics' dedication to impactful and novel therapeutic solutions.

Engaging with Partners

Registered attendees at the BIO-Europe conference will have access to Hoth's presentation schedule through the event's partnering platform, partneringONE. This feature allows for easier networking and collaborative opportunities among biopharmaceutical companies.

The Vision of Hoth Therapeutics

Founded with a mission to innovate in the therapeutic landscape, Hoth Therapeutics is dedicated to elevating drugs from early research phases to pre-clinical and clinical stages. The company focuses on a patient-centric approach, working closely with a collaborative team of scientists and healthcare professionals. Their research is geared towards discovering therapeutics that hold immense potential to change treatment paradigms and improve patient outcomes.

Hoth Therapeutics is particularly committed to developing treatments for dermatological conditions, oncology, and Alzheimer’s disease, showcasing a robust pipeline of innovative solutions that aim to meet pressing healthcare challenges head-on.

In addition to their presentations and networking, Hoth will likely discuss the role of emerging technologies and scientific breakthroughs that continue to shape the landscape of biopharmaceutical development.

As the event approaches, the healthcare community watches Hoth Therapeutics with keen interest, eager to see how they will advance discussions and collaborations that could lead to transformative healthcare solutions.

For further updates and information regarding their research and activities, interested parties are encouraged to visit Hoth Therapeutics' official website at hoththerapeutics.com.

The future looks promising as Hoth Therapeutics gears up for BIO-Europe 2025, marking another significant milestone in their journey towards pioneering healthcare advancements.